Celgene Corporation (CELG)

69.65 -0.33 (-0.472%)

IEX Real-Time Price

November 16, 2018 EST.

Nasdaq Global Select : Healthcare

Prev Close 69.98

Price Open 69.89

Volume: 9.12M

Avg Volume: 6.16M

Market Cap: 48.7B

P/E Ratio 9.45

52 Wk Range 68.91-110.81



CELG Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-10-15
699.61M
11.55M
2.67
1.65%

2018-09-28
699.6M
10.22M
2.47
1.46%

2018-09-14
699.6M
10.79M
2.49
1.54%

2018-08-31
699.6M
12.19M
2.55
1.74%




CELG Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-10-25
Q3 2018
BTO
2.02 (2)
2.03
0.01

2018-07-26
Q2 2018
BTO
1.86 (2)
1.86
0.00

2018-05-04
Q1 2018
BTO
1.78 (5)
1.61
-0.17

2018-04-26
Q1 2018
N/A
1.78 (5)
1.61
-0.17

News

Cancer Research Highlight: RedHill Biopharma Sets Up Continued Invasion Into Cancer (2018-11-15 10:56 SeekingAlpha)

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. RedHill Biopharma ( RDHL ) is …

 


Statistics

Shares Outstanding: 699.25M

Top 15 Institution Percent: 82.20

Price To Sales: 3.33

Price To Book: 10.07

Revenue: 3.48B

Gross Profit: 3.36B

Cash: 12.04B

Debt: N/A

Return On Assets: 8.77

Return On Equity: 39.32

Profit Margin: 19.66

Price History

Beta: 1.51

50-day Moving Avg: 81.53

200-day Moving Avg: 85.63

YTD Change: -34.39

5-day Change: -1.93

1-month Change: -17.36

3-month Change: -22.74

6-month Change: -14.39

1-year Change: -32.61

Revenue Per Share: 5.00

Revenue Per Employee: 466452.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Celgene Corporation

Exchange: Nasdaq Global Select

Industry: Biotechnology

Sector: Healthcare

Website: http://www.celgene.com

Celgene Corp is a biotech company that discovers, develops, and commercializes therapies designed to treat cancer and immune-inflammatory related diseases. Its registered brands are Abraxane, Istodax, Otezla, Pomalyst, Revlimid, Thalomid, Vidaza.